KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) EPS (Weighted Average and Diluted) (2016 - 2025)

Pfizer (PFE) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with -$0.29 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 514.29% to -$0.29 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.36, a 3.55% decrease, with the full-year FY2025 number at $1.36, down 3.55% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.29 for Q4 2025 at Pfizer, down from $0.62 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.27 in Q4 2021 to a low of -$0.59 in Q4 2023.
  • A 5-year average of $0.71 and a median of $0.58 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 5000.0% in 2025; the steepest drop was 514.29% in 2025.
  • Pfizer's EPS (Weighted Average and Diluted) stood at $3.27 in 2021, then crashed by 53.82% to $1.51 in 2022, then crashed by 139.07% to -$0.59 in 2023, then soared by 111.86% to $0.07 in 2024, then plummeted by 514.29% to -$0.29 in 2025.
  • Per Business Quant, the three most recent readings for PFE's EPS (Weighted Average and Diluted) are -$0.29 (Q4 2025), $0.62 (Q3 2025), and $0.51 (Q2 2025).